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ABSTRACT
Objective To assess the relationship between
osteoprotegerin (OPG) and cardiovascular death, and the
pathobiological mechanisms contributing to the
association, in acute coronary syndromes (ACS).
Design Prospective observational.
Setting Biomarker substudy of MERLIN-TIMI 36,
a randomised, placebo controlled trial of ranolazine in
non-ST elevation (NSTE)-ACS.
Patients 4463 patients with NSTE-ACS.
Interventions Ranolazine or placebo.
Main outcome measures Incidence of cardiovascular
death (CV death); additionally, heart failure (HF), cardiac
arrhythmias, inhospital ischaemia, severe recurrent
ischaemia or recurrent myocardial infarction (MI).
Results During a median follow-up of 341 days, 208
patients died of cardiovascular causes. The OPG baseline
concentration was strongly associated with both 30 day
and 1 year incidence of CV death. After adjustment for
conventional risk markers, OPG concentrations (log
transformed) remained a signiﬁcant predictor of CV
death by 30 days (HR (95% CI) 2.32 (1.30 to 4.17);
p¼0.005) and by 1 year (HR 1.85 (1.33 to 2.59);
p<0.001). Baseline levels of OPG were also an
independent predictor of new or worsening HF at
30 days (HR 2.25 (1.38 to 3.69); p¼0.001) and 1 year
(HR 1.81 (1.26 to 2.58) p¼0.001). By univariable
analysis, higher OPG was associated with both early
ischaemic and arrhythmic events. Although OPG levels
were associated with recurrent MI within 12 months,
this association was attenuated and no longer signiﬁcant
after multivariable adjustment.
Conclusions OPG is independently associated with
30 day and 1 year risk of cardiovascular mortality and HF
development after NSTE-ACS. As no independent
relationship between OPG levels and recurrent ischaemia
or MI was observed, myocardial dysfunction may be
a more important stimulus for OPG production than
ischaemia in ACS.
INTRODUCTION
The biomarker osteoprotegerin (OPG) has been
linked to coronary atherosclerosis, coronary plaque
stability and inﬂammation.
1e3 OPG is a member of
the tumour necrosis factor receptor superfamily
and was ﬁrst identiﬁed as a regulator of bone
resorption.
4 By binding the receptor activator of
nuclear factor kB ligand (RANKL), acting as a decoy
receptor to competitively inhibit RANKL interac-
tion with its receptor, RANK, OPG inhibits osteo-
clastogenesis. OPG is expressed in the vascular
system in both endothelial and smooth muscle cells
and is also present in atherosclerotic plaques and in
early atherosclerotic lesions.
5 Mice deﬁcient in OPG
develop severe osteoporosis as well as medial calci-
ﬁcation of the aorta and renal arteries.
6 In human
studies, OPG levels have been associated with
traditional cardiovascular risk factors such as
increasing age, decreased kidney function and
duration of diabetes.
7e9 It has also been associated
with prevalence and severity of peripheral vascular
disease
10 and prognosis in cerebrovascular disease.
11
In coronary artery disease (CAD), OPG has been
found to be associated with the severity
12 and
number of coronary artery plaques.
1 In addition,
OPG levels are associated with coronary artery
calciﬁcation on CT,
1 as well as the risk of developing
cardiovascular disease in the general population.
13
OPG is inversely related to indices of left
ventricular function in the general population
14 and
has been associated with the development and
progression of heart failure. Accordingly, it has
previously been shown that both experimental and
clinical heart failure is associated with increased
expression of the OPG/RANKL/RANK axis.
15
Moreover, in patients with acute myocardial
infarction (AMI), OPG levels reﬂect ﬁnal infarct
size
16 and predict outcome in patients presenting
with post-infarction heart failure (HF).
17 In a study
of 897 patients with acute coronary syndrome
(ACS), we have previously observed that OPG
levels obtained early after admission for ACS were
associated with long term all-cause mortality.
18
To evaluate the relationship between OPG and
cardiovascular outcomes and to further explore the
underlying pathobiological mechanisms contrib-
uting to the prognostic value of OPG in ACS, we
analysed baseline blood samples from 4463 partic-
ipants in the MERLIN (Metabolic Efﬁciency with
Ranolazine for Less Ischaemia in NSTE-ACS)-TIMI
36 trial, a large, well characterised, contemporary
population of patients with non-ST elevation
(NSTE)-ACS. In contrast with prior work, we
investigated the association between OPG and
cardiovascular mortality, and assessed whether the
increased risk of death associated with higher levels
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Biomarkers and heart diseaseof OPG could be attributed to one or more of the main deter-
minants of mortality after ACSdthat is, electrical instability,
left ventricular dysfunction or recurrent ischaemia. Accordingly,
we assessed associations between OPG and the incidence of
cardiac arrhythmias, HF development and recurrent ischaemic
events.
METHODS
Study population
This is a substudy of the MERLIN-TIMI 36 trial, and the
design, entry criteria and main results have been previously
described.
19 20 In brief, the MERLIN-TIMI 36 trial was a rando-
mised, controlled, multicentre study of 6560 patients with
NSTE-ACS treated with ranolazine or placebo. Eligible patients
had at least 10 min of ischaemic symptoms at rest and presented
with one of the following: elevated biomarkers of myonecrosis,
STsegment depression $0.1 mV, a history of diabetes mellitus or
an intermediate to high ($3) Thrombolysis in Myocardial
Infarction (TIMI) risk score. Exclusion criteria included persis-
tent ST segment elevation, end stage renal disease requiring
dialysis, cardiogenic shock or a life expectancy <12 months. The
primary efﬁcacy endpoint was a composite of cardiovascular
death, AMI or recurrent ischaemia during the study period. The
major safety endpoints were death from any cause and symp-
tomatic documented arrhythmia.
In this biomarker substudy, we measured OPG levels at
enrolment in all available plasma samples (n¼4463). We inves-
tigated OPG with a primary interest in the risk of cardiovascular
death. In addition, we examined the potential mechanisms
of adverse cardiovascular outcomes by assessing recurrent
ischaemia, MI or development of new or worsening HF during
follow-up, as well as development of symptomatic documented
arrhythmias on continuous ECG recordings from the ﬁrst 7 days
of follow-up. Endpoints were adjudicated by a blinded clinical
events committee. The protocol was approved by the relevant
institutional review boards, and informed consent was obtained
from all patients prior to study commencement.
Blood sampling procedures and biochemical assays
Samples of venous blood were obtained at randomisation in
ethylenediamine tetraacetic acid anticoagulated plastic tubes,
and plasma was isolated within 60 min of sample acquisition.
Plasma samples were stored in plastic cryovials at  208Co r
colder at the enrolling site until shipped to the TIMI Biomarker
Core Laboratory (Boston, Massachusetts, USA) where they were
maintained at  808C or colder. The samples were shipped to
Aarhus University Hospital, Aarhus, Denmark, for analysis.
Plasma levels of OPG were quantiﬁed by an inhouse time
resolved immunoﬂuorometric assay, using commercially avail-
able monoclonal antibodies (DY085E from R&D Systems,
Abingdon, UK). The method has been described previously.
21
The limit of detection was 15 ng/l. A plasma control was
included in every OPG assay. The intra- and inter-assay varia-
tions (%) were below 5% and 9%, respectively, at concentration
of 1000 ng/l. In a population based sample of 216 subjects (39%
male, mean age 43 (SD 11) years) without a history of cardio-
vascular disease, hypertension or diabetes, the median OPG
concentration was 1164 ng/l (5th percentile 733 ng/l, 95th
percentile 2211 ng/l). C reactive protein (CRP) was measured by
an established high sensitivity (hs) nephelometric method
(Siemens). The assay range for hs-CRP was 0.05e10 mg/l, with
a limit of detection of 0.03 mg/l and coefﬁcient of variation of
5.1%, 2.2% and 2.5% at hs-CRP concentrations of 0.17, 1.16 and
1.88 mg/l, respectively. Levels of cardiac troponin I (cTnI) were
measured using the TnI ultra assay (Siemens Healthcare Diag-
nostics Inc, Deerﬁeld, Illinois, USA) and B type natriuretic
peptide (BNP) was measured using the ADVIA Centaur
(Siemens Healthcare Diagnostics Inc, Deerﬁeld, Illinois, USA).
The assay for cTnI has a lower level of detection of 6 ng/l,
a 99th percentile value of 40 ng/l and a total imprecision of 10%
at a concentration of 30 ng/l.
22 For BNP, the decision limit was
80 ng/l.
23 24 The assay range for BNP was 0.5e5000 ng/l with
a coefﬁcient of variation of 3.4%, 2.9% and 2.4% at BNP
concentrations of 48, 461 and 1768 ng/l, respectively. All
biomarker testing was performed by personnel blinded to clinical
outcomes and treatment allocation.
Statistical analysis
Plasma concentrations of OPG are reported using the median
and IQR of values. Cut-offs for OPG categories correspond to
the 33rd and 67th percentiles. Categorical baseline characteris-
tics were compared using c
2 tests for categorical variables and
are presented as proportions; continuous variables were
compared using the Wilcoxon rank sum test. Multivariate
logistic regression analysis was performed to identify indepen-
dent predictors of increased circulating OPG levels at baseline.
Cox proportional hazard regression was performed to assess
associations between OPG levels and the outcome measures at
the 30 day and 1 year follow-up periods.
Both unadjusted and covariate adjusted analyses were
performed. In the covariate adjusted analysis, all elements of the
TIMI risk score for NSTE-ACS, including cTnI ultra, as well as
history of chronic HF, creatinine clearance <60 ml/min, gender,
BMI, BNP and CRP were included. OPG was entered both as
a continuous (log transformed) variable and as a categorical
variable (ie, divided in tertiles). The discriminative value of
adding OPG to a predeﬁned risk model was evaluated by
calculating the category-less net reclassiﬁcation improvement.
25
Analysis was performed using STATA V.10.1 (StataCorp). A
p value (two tailed) <0.05 was considered to indicate statistical
signiﬁcance.
RESULTS
Baseline characteristics
Median time from onset of ischaemic symptoms to random-
isation was 24 h (IQR 13e34 h). Median value of OPG was
1632 ng/l (IQR 1206e2242 ng/l), and cut-off levels between
tertiles were 1345 ng/l and 2000 ng/l, respectively. There was
a very weak, but statistically signiﬁcant, association between
time from symptom onset and OPG levels at baseline (r¼0.03;
p¼0.022). Characteristics of the patients according to OPG
tertile 3 versus tertiles 1 and 2 at baseline are shown in table 1.
Patients with higher OPG levels were more likely to be older, to
be female, to have an index diagnosis of NSTEMI, a left
ventricular ejection fraction #50%, a BNP value >80 ng/l and
a positive cTnI (table 2). A history of diabetes, hypertension,
chronic HF and impaired renal function, expressed as estimated
creatinine clearance <60 ml/min, were more frequent in the
highest versus the two lower OPG tertiles. In addition, in
patients without known diabetes, a fasting glucose >7 mmol/l
(126 mg/100 ml) or non-fasting glucose $11 mmol/l (200 mg/
100 ml) was more frequent in the highest versus the two
lower OPG tertiles (p¼0.009). In contrast, a history of dyslipi-
daemia, a family history of CAD and to be a current smoker
were more frequent in the two lower OPG tertiles. The
frequency of prior angina, MI, percutaneous coronary interven-
tion or coronary artery bypass graft did not differ between the
third versus the ﬁrst and second OPG tertiles. By multivariable
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Biomarkers and heart diseaselogistic regression analysis, age $75 years, a history of diabetes
and estimated creatinine clearance <60 ml/min were the
variables most closely associated with higher baseline OPG levels
(table 3).
Relationship to cardiovascular death
During a median follow-up time of 341 days, 208 patients died
of cardiovascular causes. The concentration of OPG at baseline
was strongly associated with cardiovascular mortality at both
30 days and 1 year (ﬁgure 1). By univariable analysis, the HR
associated with 1 SD increase in logarithmically transformed
OPG levels at baseline was 4.67 (95% CI 2.85 to 7.67; p<0.001)
at 30 days and 3.85 (95% CI 2.92 to 5.08; p<0.001) after 1 year
(table 4). After adjustment for conventional risk markers,
including TIMI risk score covariates, a history of chronic HF,
creatinine clearance <60 ml/min, gender, BMI, BNP, CRP and
OPG concentrations remained signiﬁcantly associated with
cardiovascular mortality after 30 days (HR (95% CI) 2.32 (1.30
to 4.17); p¼0.005) and 1 year (HR 1.85 (1.33 to 2.59); p<0.001).
Comparing the third versus the ﬁrst and second tertiles yielded
an adjusted HR of 2.14 (1.21 to 3.80; p¼0.009) for cardiovascular
mortality at 30 days and 1.78 (1.31 to 2.43; p<0.001) at 1 year.
By net reclassiﬁcation analysis, adding OPG tertile 3 versus
tertiles 1 and 2 to a risk marker model including TIMI risk score
covariates, BMI, BNPand CRP resulted in signiﬁcantly improved
reclassiﬁcation of patients (p<0.0001).
Exploratory univariable analyses were performed to assess the
relationships between OPG and subcategories of cardiovascular
death. OPG was associated with the incidence of sudden death
(n¼85, HR 2.19 (1.43 to 3.36)), the incidence of fatal HF
secondary to coronary atherosclerotic disease (n¼38, HR 7.20
(3.41 to 15.22)) as well as with the incidence of other coronary
atherosclerotic deaths (n¼113, HR 2.51 (1.73 to 3.63)).
Relationship to HF hospitalisation
One hundred seventy-seven patients were hospitalised for HF
during the ﬁrst year after ACS. By multivariable analysis, a 1 SD
increase in logarithmically transformed OPG levels at baseline
was associated with increased risk of HF hospitalisation (HR
1.81 (1.26 to 2.58) p¼0.001) (table 4). Comparing the third
versus the ﬁrst and second tertiles yielded an HR of 3.04 (2.26 to
4.11; p¼0.001) for HF hospitalisation. By multivariable analysis,
OPG in the third tertile was associated with increased risk of
hospitalisation for HF within 30 days (HR 1.77 (1.11 to 2.82);
p¼0.017) and 1 year (HR 1.70 (1.22 to 2.36); p¼0.002). In
a subgroup analysis of patients with BNP <80 ng/l, higher OPG
levels were still signiﬁcantly associated with hospitalisation for
HF (p¼0.0059). Adding OPG tertile 3 versus tertiles 1 and 2 to
Table 1 Baseline characteristics
OPG tertile 3 (%) n N OPG tertiles 1 and 2 (%) n N p Value
Randomisation group (ranolazine) 48.4 719 1485 49.8 1484 2978 0.37
Age $75 years 30.1 447 1485 9.9 296 2978 <0.001
Gender (male) 59.1 878 1485 67.7 2017 2978 <0.001
Race (Caucasian) 96.7 1436 1485 96.8 2882 2978 0.89
BMI group
BMI <25 kg/m
2 24.6 361 1465 18.5 545 2943 <0.001
BMI 25e<30 kg/m
2 41.0 600 1465 43.6 1283 2943
BMI $30 kg/m
2 34.4 504 1465 37.9 1115 2943
Index diagnosis
Unstable angina 41.1 611 1485 53.1 1582 2978 <0.001
NSTEMI 56.7 842 1485 44.1 1312 2978
Other 2.2 32 1485 2.8 84 2978
Increased glucose* 7.9 66 836 5.4 113 2112 0.009
History of diabetes 42.4 629 1485 27.8 827 2978 <0.001
History of hypertension 77.5 1145 1478 73.1 2165 2960 0.0018
History of dyslipidaemia 63.5 847 1334 69.9 1899 2715 <0.001
Current smoker 19.6 291 1485 27.9 829 2976 <0.001
History of CHF 23.3 346 1485 19.5 582 2978 0.0036
Family history of CAD 33.3 443 1330 42.9 1205 2812 <0.001
Prior angina 58.9 847 1438 59.8 1755 2933 0.55
Prior myocardial infarction 35.5 521 1466 36.0 1062 2954 0.79
Prior PCI 19.7 291 1475 20.8 618 2965 0.39
Prior CABG 13.1 194 1483 11.2 332 2977 0.060
Creatinine clearance <60 ml/min 33.2 490 1478 13.7 407 2969 <0.001
TIMI risk score <0.001
0e2 17.2 255 1485 28.2 839 2978
3e4 53.7 798 1485 53.6 1597 2978
$5 29.1 432 1485 18.2 542 2978
Aspiriny 95.6 1420 1485 96.8 2882 2978 0.05
Clopidogrel 65.3 970 1485 62.2 1852 2978 0.041
Beta blocker 89.7 1332 1485 90.4 2692 2978 0.46
ACE-I or ARB 81.3 1208 1485 76.8 2286 2978 0.0005
Statin 78.2 1162 1485 79.0 2352 2978 0.57
*Fasting glucose >7.0 mmol/l (126 mg/100 ml) or non-fasting glucose $11.1 mmol/l (200 mg/100 ml).
yDuring hospitalisation or at discharge.
ACE-I, ACE inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CABG, coronary artery bypass graft; CAD, coronary artery disease; CHF, congestive heart failure;
NSTEMI, non-ST elevation myocardial infarction; OPG, osteoprotegerin; PCI, percutaneous coronary intervention; TIMI, Thrombolysis in Myocardial Infarction.
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Biomarkers and heart diseasea risk marker model that included BNP and hs-CRP resulted in
signiﬁcantly improved reclassiﬁcation of patients (p<0.0001).
Relation to coronary anatomy, inhospital ischaemia and
inhospital cardiac arrhythmias
Among patients undergoing coronary angiography (n¼2476),
patients with elevated OPG were more likely to have multivessel
($2) CAD and disease involving the left anterior descending
artery (table 2). Within the ﬁrst 7 days of follow-up, 892
patients had signiﬁcant ischaemic events and 3413 patients had
signiﬁcant arrhythmia on Holter recordings. Both ischaemic and
signiﬁcant arrhythmic events were signiﬁcantly more frequent
in the upper OPG versus the two lower tertiles during the ﬁrst
7 days of follow-up but these relationships were attenuated after
adjustment for patient age. The number of patients with
signiﬁcant ventricular tachycardia (ie, $8 beats) did not differ
according to OPG tertile.
Relationship to recurrent ischaemia and myocardial infarction
at 30 days and 1 year
In contrast with the ﬁndings inhospital, the risk of experiencing
recurrent ischaemia, deﬁned as severe recurrent ischaemic events
leading to hospitalisation or revascularization and worsening
angina requiring intensiﬁcation of medical therapy, at 30 days
and 1 year was not associated with OPG levels. However, 86
patients in the ﬁrst OPG tertile, 115 in the second and 135
patients in the third tertile experienced an AMI during the
12 months after the index event. Thus, by univariable analysis,
OPG was associated with the 1 year incidence of recurrent MI
(HR 1.67 (1.33 to 2.09); p¼0.001). In a multivariable model,
however, this association was attenuated and no longer signiﬁ-
cant (table 4).
Relationship with treatment allocation or ejection fraction
determination
No interaction between OPG levels and treatment allo-
cation was found. Moreover, for the endpoints of cardio-
vascular mortality or HF, no interaction was observed between
OPG levels and access to left ventricular ejection fraction
determination.
DISCUSSION
In this large study of well characterised patients with NSTE-ACS,
the main ﬁnding was that OPG is robustly and independently
associated with the 30 day and 1 year risk of cardiovascular
mortality and hospitalisation for HF. These associations trans-
lated into a signiﬁcant reclassiﬁcation of the risk of both
cardiovascular death and HF hospitalisations. Although OPG was
related to the angiographic severity of CAD and ischaemia on
Holter recording during the ﬁrst 7 days, no association with the
incidence of recurrent AMI or of cardiac arrhythmias was
observed after multivariable adjustment. These ﬁndings point
towards additional mechanistic assessment that will help eluci-
date whether OPG related pathways are a potential therapeutic
target in the prevention and management of cardiovascular
disease.
Clinical and research implications
We have previously shown an association between OPG levels
and all-cause mortality among 897 patients across the spectrum
Table 2 Osteoprotegerin and the severity of structural heart disease
OPG tertile 3 (%) n cases N total OPG tertiles 1 and 2 (%) n cases N total p Value
BNP >80 ng/l 56.7 842 1484 35.6 1060 2978 <0.001
TnI ultra positive ($40 ng/l) 73.1 1069 1463 60.4 1787 2959 <0.001
Disease extent ($50%)*
None 10.4 84 807 12.1 202 1669 <0.001
One VD 22.6 182 807 31.4 524 1669
Two VD 25.5 206 807 24.0 400 1669
Three VD or LM 41.5 335 807 32.5 543 1669
LVEF (<50%)y 45.7 454 994 35.3 706 2000 <0.001
*Among 2476 patients with angiographic data available.
yAmong 2994 patients with LVEF available.
BNP, B type natriuretic peptide; LM, left main; LVEF, left ventricular ejection fraction; OPG, osteoprotegerin; TnI, troponin I; VD, vessel disease.
Table 3 Independent predictors of higher circulating osteoprotegerin
(tertile 3) at baseline
Variable OR (95% CI) p Value
Age (>75 years) 2.18 (1.76 to 2.72) <0.001
Creatinine clearance <60 ml/min 1.80 (1.46 to 2.23) <0.001
Baseline BNP (>80 ng/l) 1.60 (1.36 to 1.89) <0.001
History of hypercholesterolaemia (yes) 0.70 (0.59 to 0.82) <0.001
History of diabetes (yes) 2.04 (1.73 to 2.41) <0.001
History of heart failure (yes) 1.46 (1.19 to 1.80) <0.001
Gender (males) 0.76 (0.64 to 0.89) 0.001
Region: Eastern Europe (referent North America) 0.74 (0.59 to 0.93) 0.010
Region: Western Europe (referent North America) 1.33 (1.08 to 1.63) 0.006
Index event NSTEMI (referent UA) 1.34 (1.10 to 1.62) 0.003
Family history of CAD 0.83 (0.70 to 0.97) 0.021
TnI ultra positive ($40 ng/l) 1.24 (1.01 to 1.53) 0.042
BNP, B type natriuretic peptide; CAD, coronary artery disease; NSTEMI, non-ST elevation
myocardial infarction; TnI, troponin I; UA, unstable angina.
Figure 1 KaplaneMeier curves of cardiovascular mortality by tertiles
of osteoprotegerin (OPG) at baseline.
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Biomarkers and heart diseaseof ACS followed for 89 months.
18 However, the pathobiological
mechanisms underlying the association between OPG and
mortality have remained elusive. Theoretically, OPG could
reﬂect one or more of the following: atherosclerotic burden,
myocardial ischaemia, arrhythmia risk or the degree of ventric-
ular dysfunction. For instance, observations from epidemiolog-
ical studies of the general population have suggested that OPG is
independently associated with the extent of coronary and aortic
atherosclerosis,
1 myocardial anatomy and function,
14 and the
risk of atrial ﬁbrillation.
26 However, to what extent these
mechanisms are operative and relevant to the association
between OPG and survival in the setting of NSTE-ACS is
unclear.
We have now demonstrated that OPG is independently and
strongly associated with cardiovascular mortality both early after
presentation (at 30 days) and in the longer term. In addition, our
current large scale study, which prospectively collected data on
coronary anatomy, myocardial ischaemia, cardiac arrhythmias
and HF, has provided new insight relating these potential
mechanisms to the association between OPG and cardiovascular
mortality. The current data suggest that HF rather than
myocardial ischaemia or cardiac arrhythmias is the principal
factor explaining the increased risk of death associated with
higher circulating OPG levels in the setting of NSTE-ACS. These
ﬁndings extend previous observations in smaller studies of an
association between OPG and long term risk of HF after ACS
18
and between OPG and risk of mortality in patients with AMI
complicated by HF,
17 as well as of data demonstrating associa-
tions between OPG and ﬁnal infarct size,
16 and between OPG
levels and mortality in patients with chronic HF.
21 27 Moreover,
our ﬁndings are compatible with experimental data showing that
myocardial OPG gene expression and protein content are
increased in HF,
15 which suggests that OPG might play a role in
left ventricular remodelling and the progression of HF.
We also observed an association between the extent of
atherosclerosis on coronary angiography and OPG levels.
However, as the extent of atherosclerosis is also associated with
the degree of ventricular dysfunction, the extent of atheroscle-
rosis could be an epiphenomenon or mediator of the association
between OPG and ventricular dysfunction. In fact, controversy
exists as to whether or not OPG is related to progression of
atherosclerosis. Although some epidemiological data suggest
that OPG is related to the extent of coronary atherosclerosis and
calciﬁcations,
1 this ﬁnding has not been conﬁrmed by others.
13
Recent experimental data also suggest that OPG may play
a protective role with regard to progression of atherosclerosis.
For instance, mice genetically modiﬁed to not express OPG
demonstrate accelerated advanced lesion progression,
28 and in
a mouse model, treatment with recombinant OPG was associ-
ated with stabilisation of atherosclerotic plaques by promoting
smooth muscle cell and collagen accumulation.
3 In human
studies, however, treatment with recombinant OPG has not
been associated with altered risk of cardiovascular events.
29 30
Patients with ACS, in particular in those complicated by left
ventricular dysfunction or HF, are at increased risk of ventricular
arrhythmias and sudden cardiac death. Moreover, recent data
have suggested that OPG is related to the development of new
onset atrial ﬁbrillation.
26 We have previously shown that OPG
levels are associated with mortality in patients with HF of
both ischaemic and non-ischaemic origin,
21 and we therefore
hypothesised that part of the explanation for the association
between OPG levels and increased risk of mortality after NSTE-
ACS might be that OPG levels are associated with the risk of
recurrent arrhythmic events. Although the number of patients
experiencing signiﬁcant arrhythmic events and sudden cardiac
death increased with OPG concentration, this association was
attenuated after multivariable adjustment.
Strength and limitations
The strengths of the current study include the large and well
characterised contemporary cohort of NSTE-ACS patients.
Study limitations include the fact that patients with suspected
NSTE-ACS recruited in a clinical trial may not accurately reﬂect
or be entirely generalisable to the broad unselected population of
patients with acute chest pain. Although we found evidence of
added value of OPG in risk reclassiﬁcation for the endpoints
cardiovascular death and HF, the clinical relevance of OPG will
depend on whether or not therapeutic relevance is established.
CONCLUSION
OPG is robustly associated with 30 day and 1 year risk of
cardiovascular mortality and HF development but not recurrent
ischaemia or MI. These ﬁndings suggest that left ventricular
dysfunction, rather than myocardial ischaemia, is the more
important mediator of the adverse prognosis indicated by
elevation of OPG in ACS. Our ﬁndings in this well characterised
patient population add to the emerging evidence supporting
involvement of OPG in the pathophysiology of ACS and its
consequences, and support investigation of therapies that might
modify this risk, including the elucidation of OPG related
pathways that might be evaluated as targets for intervention.
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Table 4 Associations between osteoprotegerin concentrations (continuous) and events during follow-up
30 day outcomes 1 year outcomes
Unadjusted Adjusted Unadjusted Adjusted
HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value
CV death 4.67 (2.85 to 7.67) <0.001 2.32 (1.30 to 4.17) 0.005 3.85 (2.92 to 5.08) <0.001 1.85 (1.33 to 2.59) <0.001
Severe recurrent ischemia 1.23 (0.90 to 1.69) 0.19 0.93 (0.65 to 1.33) 0.69 1.16 (0.95 to 1.40) 0.14 1.04 (0.83 to 1.29) 0.73
MI 1.57 (1.13 to 2.17) 0.006 1.11 (0.76 to 1.61) 0.59 1.67 (1.33 to 2.09) <0.001 1.13 (0.87 to 1.46) 0.37
Hospitalisation for New or
Worsening HF
4.70 (3.10 to 7.12) <0.001 2.25 (1.38 to 3.69) 0.001 4.11 (3.04 to 5.54) <0.001 1.81 (1.26 to 2.58) 0.001
CV death or MI 2.04 (1.53 to 2.71) <0.001 1.35 (0.97 to 1.88) 0.072 2.17 (1.80 to 2.62) <0.001 1.37 (1.10 to 1.70) 0.005
CV death or hospitalisation for
new or worsening HF
4.38 (3.07 to 6.25) <0.001 2.14 (1.40 to 3.25) <0.001 3.55 (2.83 to 4.47) <0.001 1.69 (1.28 to 2.22) <0.001
HR associated with 1 SD increase in logarithmically transformed osteoprotegerin levels at baseline.
Adjusted for Thrombolysis in Myocardial Infarction risk score covariates (including cardiac marker), history of congestive heart failure, creatinine clearance <60 ml/min, gender, body mass
index (continuous), B type natriuretic peptide (log transformed) and C reactive protein (log transformed).
CV, cardiovascular; HF, heart failure; MI, myocardial infarction.
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